[1] Rambaldi PF,Mansi L,Procaini E,et al.Breast can-cer detestion with 99Tcm-tetrofosmin[J].Clin Nucl Med,1995,20:703-705.
[2] Mansi L,Rambaldi PF,Cuccurullo V,et al.Diagnos-tic and prognostic role of 99Tcm-tetrofosmin in breast cancer[J].Q J Nucl Med,1997,41:239-250.
[3] Arbab AS,Koizumi K,Toyama K,et al.Uptake of technetium-99m-tetrofosmin,technetium-99m-MIBI and thallium-201 in tumor cell lines[J].J Nucl Med,1996,37:1551-1556.
[4] De Jong M,Bernard BF,Breeman WAP,et al.Com-parison of uptake of 99Tcm-MIBI,99Tcm-tetrofosmin and 99Tcm-Q12 into human breast cancer cell lines[J].Eur JNucl M ed,1996,23:1361-1366.
[5] Ballinger JR,Bannerman J,Boxen I,et al.Tech-netium-99m-tetrofosmin as a substrate for P-glycopro-tein:in vitro studies in multidrugresistant breast tu-mor cells[J].J Nucl Med,1996,37:1578-1582.
[6] Higley B,Smith FW,Smith T,et al.Technetium-99m-1,2-bis[bis (2-ethoxyethyl) phosphino] ethane:hu-man biodistribution,dosimetry and safety of a new myocardial perfusion imaging agent[J].J Nucl Med,1993,34:30-38.
[7] Mansi L,Rambaldi PF,Procaccini E,et al.Scinti-mammography with technetium-99m-tetrofosmin in the diagnosis of breast cancer and lymph node metas-tases[J].Eur J Nucl Med,1996,23:932-939.
[8] Batista JF,Solano ME,Oliva JP,et al.Usefulness of 99Tcm-tetrofosmin scintimammography in palpable breast tumours[J].Nucl Med Commun,1997,18:338-340.
[9] Buscombe JR,Cwikla JB,Thakrar DS,et al.Prone SPET scintimammography[J].Nucl Med Commun,1999,20:237-245.
[10] Adalet I,Demirkol MO,Muslumanoglu M,et al.99Tcm-tetrofosmin scintigraphy in the evaluation of pal-pable breast masses[J].Nucl Med Commun,1997,18:118-121.
[11] Akcay MN,Akin Y,Karabag B,et al.99Tcm-tetrofos-min in breast carcinoma and axillary Iymph node metastases:a comparative study with 99Tcm-MIBI[J].Clin Nucl Med,1997,22:832-834.
[12] Takayame T,Kinuya S,Sugiyama M,et al.99Tcm-tetrofosmin scintimammography in palpable breast tu-mours[J].Ann Nucl Med,1998,12:293-296.
[13] Lacic M,Bokulic T,Lukac J,et al.Bone marrow im-munoscintigraphy for the detection of skeletal metas-tases in patients with breast cancer[J].Nucl Med Commun,1999,20:135-143.
[14] Keshtgar M RS,Ell PJ.Sentinel lymph node detection and imaging[J].Eur J Nucl Med,1999,26:57-67.
[15] Kabasakal L,Halac M,Nisli C,et al.The effect of P-glycoprotein function inhibition with cyclosporine A on the biodistribution of Tc-99m sestamibi[J].Clin Nucl Med,2000,25:20-23.
[16] Yutani K,Tatsumi M,Shiba E,et al.Comparison of dual-head coincidence gamma camera FDG PET in de-tection of breast cancer and axillary lymph node metas-tasis[J].JNucl Med,1999,40:1003-1008.
[17] Rostom AY,Powe J,Kandil A,et al.Positron emis-sion tomography in breast cancer:a clinico-pathologi-cal correlation of results[J].Br J Radiol,1999,72:1064-1068.
[18] Bleckmann C,Dose J,Bohuslavizki KH,et al.Effect of attenuation correction on lesion detectability in FDG PET of breast cancer[J].JNucl Med,1999,40:2021-2024.
[19] Amano S,Inoue T,Tomiyoshi K,et al.In vivo com-parison of PET and SPECT radiopharmaceuticals in detecting breast cancer[J].J Nucl Med,1998,39:1424-1427.
[20] Dehdashti F,Flanagan FL,Mortimer JE,et al.Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy[J].Eur J Nucl Med,1999,26:51-56.
[21] Fischer U,Kopka L,Grabbe E.Breast carcinoma:ef-fect of preoperative constrast-enhanced MR imaging on the therapeutic approach[J].Radiology,1999,213:881-888.
[22] Chen DR,Chang PF,Huang YL.Computer-aided di-agnosis applied to U S of solid breast nodules by using neural networks[J].Radiology,1999,213:407-412.
[23] Zonderland HM,Coerkamp E,Hermans J,et al.Di-agnosis of breast cancer of contribution of US as an ad-junct to mammography[J].Radiology,1999,213:413-422.